Get notified regarding key financial metrics and revenue changes at CSL BehringLearn more
Banner background

Summary - Funding Rounds

Founding Date

1904
CSL Behring is a subsidiary of CSL

CSL Behring Revenue Breakdown

Embed Graph

CSL Behring revenue breakdown by business segment: 51.1% from Immunoglobulins, 14.3% from Hemophilia, 8.1% from Albumin, 21.6% from Specialty and 4.8% from Other

CSL Behring Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

6.8b7.3b7.9b

Revenue growth, %

8%7%

Gross profit

3.9b4.2b4.5b

Gross profit Margin, %

57%57%58%

Operating expense total

321.0m352.7m

Depreciation and amortization

252.4m321.0m352.7m

EBITDA

2.6b2.7b2.8b

EBITDA margin, %

38%36%36%

EBIT

2.3b2.4b2.5b

EBIT margin, %

34%32%31%

CSL Behring Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Total Assets

10.6b11.2b14.2b

Total Liabilities

6.5b6.7b8.5b

CSL Behring Ratios

USDFY, 2018

Revenue/Employee

1.6m

CSL Behring Operating Metrics

Sep, 2020Dec, 2020

Countries

100

Patent Applications

3

Patents

1

Plasma Collection Centers

275

Trademark Applications

1

Trademarks

4

CSL Behring Employee Rating

3.4435 votes
Culture & Values
3.5
Work/Life Balance
3.4
Senior Management
3.1
Salary & Benefits
3.7
Career Opportunities
3.3
Source